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The intestinal mucosa in inflammatory bowel disease (IBD) contains increased
frequencies of lymphocytes and a disproportionate increase in plasma cells secreting
immunoglobulin (Ig)G relative to other isotypes compared to healthy controls. Despite
consistent evidence of B lineage cells in the mucosa in IBD, little is known of B cell
recruitment to the gut in IBD. Here we analyzed B cells in blood of patients with
Crohn’s disease (CD) and ulcerative colitis (UC) with a range of disease activities. We
analyzed the frequencies of known B cell subsets in blood and observed a consistent
reduction in the proportion of CD27−IgD− B cells expressing all Ig isotypes in the blood
in IBD (independent of severity of disease and treatment) compared to healthy controls.
Successful treatment of patients with biologic therapies did not change the profile of
B cell subsets in blood. By mass cytometry we demonstrated that CD27−IgD− B cells
were proportionately enriched in the gut-associated lymphoid tissue (GALT) in IBD. Since
production of TNFα is a feature of IBD relevant to therapies, we sought to determine
whether B cells in GALT or the CD27−IgD− subset in particular could contribute to
pathology by secretion of TNFα or IL-10. We found that donor matched GALT and
blood B cells are capable of producing TNFα as well as IL-10, but we saw no evidence
that CD27−IgD− B cells from blood expressed more TNFα compared to other subsets.
The reduced proportion of CD27−IgD− B cells in blood and the increased proportion in
the gut implies that CD27−IgD− B cells are recruited from the blood to the gut in IBD.
CD27−IgD− B cells have been implicated in immune responses to intestinal bacteria and
recruitment to GALT, and may contribute to the intestinal inflammatory milieu in IBD.
Keywords: memory B cells, inflammatory bowel disease, GALT, mass cytometry, biologics, ustekinumab,
infliximab
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INTRODUCTION
Inflammatory bowel disease (IBD) encompasses two clinical
entities: Crohn’s disease (CD) and ulcerative colitis (UC). Both
are chronic debilitating diseases characterized by relapsing
intestinal inflammation. While the exact etiology of both
diseases is still not clearly understood, current literature suggests
that an aberrant immune response to the intestinal flora
contributes to pathology in genetically susceptible individuals
(1–3). The evidence for this is however stronger for CD
than for UC (4), which can be associated with autoimmune
conditions like primary sclerosing cholangitis (PSC) in a small
subgroup of patients (5). CD is a condition hallmarked by
granulomatous transmural inflammation that can affect the
entire gastrointestinal tract and is frequently complicated by
fistulae and strictures. In contrast, UC is predominantly a
disease affecting the rectum and distal colon, where it manifests
as ulceration limited to the mucosal layer. However, rectum-
sparing forms of UC are known to exist and in rare cases the
pathology can extend into the terminal ileum (6, 7). Whilst big
strides have been made in developing biologic therapies for both
diseases, a significant proportion of patients with CD and UC
remain treatment refractory, highlighting the unmet need for
a better understanding of the mechanisms contributing to the
pathogenesis of both diseases (8, 9).
Most immunological research in CD and UC has focused on
T lymphocytes and macrophages that infiltrate the mucosa in
active disease (10–12). Th1 and Th17 cells have been implicated
especially in the pathogenesis of CD, whilst their role in UC is
still not fully understood (13, 14). UC is also characterized by the
infiltration of neutrophils into the inflamed mucosa, where they
are proposed to have a pathogenic role by the maintenance of
inflammation (15). However, in both CD and UC, a significant
increase in the number of plasma cells in the lamina propria has
been observed and linked to disease pathogenesis (16–18).
The gut-associated lymphoid tissue (GALT) comprises the
appendix, Peyer’s patches in the ileum and isolated lymphoid
follicles in the small and large intestine. GALT is the inductive site
for the generation of protective immune responses against enteric
pathogens as well as the tolerogenic response to commensal
species (19). Interestingly, the appendicectomy of the (inflamed)
appendix at a young age has been correlated with a reduced risk
of developing UC later in life (20). The underlying mechanism
of this protective effect is unknown; however, it strongly
suggests that an aberrant immune response in the appendix can
predispose to UC. In addition, several reports have described
appendiceal inflammation in patients with UC affecting only the
distal parts of the colon (21, 22). Based on these studies that
suggest that plasma cells, B cells and GALT could be implicated
in the development of IBD, we sought to study the B cell
populations in blood and GALT of CD and UC patients. In
addition, we aimed to study the gut-homing capacity of the
different populations in blood by investigating the expression of
Abbreviations: IBD, inflammatory bowel disease; UC, ulcerative colitis; CD,
Crohn’s disease; HC, healthy control; CRP, C-reactive peptide; GALT, gut-
associated lymphoid tissue.
the β7 subunit of α4β7 integrin in active disease vs. remission.
We further looked at how the three main biologic treatments for
IBD, the anti-TNF treatment infliximab, the anti-α4β7 integrin
treatment vedolizumab, and the anti-IL12/IL23 p40 antibody
ustekinumab affect peripheral B cell subsets in IBD.While several
B cell aberrations in blood and GALT in IBD were observed,
we focus this report on the poorly understood CD27−IgD−
population that are likely to be unconventional memory B cells
(23–27), that we found to be consistently depleted in CD and UC
blood, but enriched in GALT.
MATERIALS AND METHODS
Sample Collection
All recruited IBD patients had a confirmed diagnosis of either CD
or UC and took part with informed written consent. The study
was approved by the local ethics committee (REC 10/H0704 and
REC 15/LO/2127). Blood samples were obtained from patients
who attended the biologics infusion clinic or the outpatient IBD
clinic for a routine review. Controls for the study of blood
cells were healthy donors who were age and gender matched
to the patients in each group. Endoscopic samples were taken
from IBD patients undergoing routine colonoscopies to assess
disease activity, and from patients undergoing polypectomy who
had no signs of intestinal inflammation, serving as controls.
GALT samples were obtained by targeted biopsies of ileal
Peyer’s patches and the appendiceal orifice. Mononuclear cells
from biopsies were isolated using a collagenase digest as
previously described (28). Blood samples were collected in
sodium heparin tubes and peripheral blood mononuclear cells
(PBMCs) were isolated using Ficoll-Paque (GE Healthcare,
Amersham, UK) density gradient centrifugation as previously
described (28). PBMCs were cryopreserved using fetal bovine
serum (FBS)/10% dimethyl sulfoxide (DMSO; both Sigma
Aldrich, Gillingham, UK) and stored in the vapor phase of liquid
nitrogen until use. An overview of recruited patients is provided
in Supplemental Tables 1, 2. For cell sorting experiments blood
cones from healthy donors were purchased from NHS Blood and
Transplant (Tooting, UK).
Patient Stratification
We included 10 patients receiving infliximab (8CD and 2 UC;
55% female, median age 41); six patients receiving vedolizumab
(1CD and 5 UC, 50% female, median age 32), and 14CD
patients receiving ustekinumab (50% female, median age 32).
Patients received:
- Intravenous (IV) ustekinumab (Stelara R©) 6mg/kg (induction)
and 90mg subcutaneously every 8 weeks from week 8.
- IV infliximab (Remsima R©) 5 mg/kg at week 0, 2, and 6
thereafter every 8 weeks.
- IV vedolizumab (Entyvio R©) 300mg at week 0, 2, and 6 and
thereafter every 8 weeks.
Blood samples were prospectively collected pre-treatment (week
0), at 6 weeks (infliximab and vedolizumab) or 8 weeks
(ustekinumab). Clinical response/remission was assessed at week
14 (infliximab and vedolizumab) or week 16 (ustekinumab).
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Clinical remission was defined as Harvey-Bradshaw index (HBI)
<5 or partial Mayo score 0–1 at week 14/16 (29, 30). Clinical
response was defined as HBI reduction ≥3 or partial Mayo
score reduction >/=2 for patients with inactive disease at
baseline, or >30% reduction if disease activity index was
abnormal (HBI ≥5, partial Mayo ≥2) at week 0. Biological
response was defined as a 50% reduction in CRP, if baseline
CRP >5 mg/l. Biological remission was defined as CRP
<5 mg/l (31).
Multi-Parameter Flow Cytometry
Frozen PBMCs from healthy volunteers and IBD patients were
thawed, washed and rested for 45min in RPMI-1640 containing
10% FBS, 100 U/ml penicillin/ 100µg/ml streptomycin (all
Gibco/Thermo Fisher Scientific, Waltham, MA, USA), with
DNase I (0.1 mg/ml; from Roche, Welwyn Garden City, UK).
Cells were resuspended in PBS prior to live dead staining
with Zombie Aqua (Biolegend, San Diego, CA, USA). Cells
were then stained with fluorochrome conjugated monoclonal
antibodies to CD19, CD27, CD10, IgA, IgD, IgM, and integrin
β7 (Supplemental Table 3). Cells were analyzed using a BD
Biosciences LSR Fortessa flow cytometer (Wokingham, UK)
before determination of B cell populations using the gating
strategy shown in Figure 1. Further detail and explanation are
provided in Supplemental Figure 1 and Supplemental Table 4.
IgG was not used in the flow cytometry panel, but preliminary
experiments demonstrated that cells lacking IgM, IgA (and IgD
for the CD27− subset) could be reasonably classified as IgG+,
so this method was used to reduce antibodies in the panel. One
of five test experiments is illustrated in Supplemental Figure 2.
Although theoretically IgE expressing B cells could have been
included, these are known to be very small in number and
are difficult to detect due to the possibility of IgE binding to
Fc receptors.
Cell Sorting
Frozen blood cone derived PBMCs were thawed, washed and
rested in RPMI-1640 containing 10% FBS, 100 U/ml penicillin/
100µg/ml streptomycin, and DNase I (0.1 mg/ml) for 45min.
Cells were stained with DAPI, anti-CD19, CD27, and IgD
prior to sorting using a BD Biosciences FACSAria II Cell
Sorter. B cells were sorted initially by CD19 expression, with
four populations isolated based on CD27 and IgD expression:
CD27+IgD−, CD27−IgD−, CD27+IgD+, and CD27−IgD+
(Supplemental Figure 3A).
Analysis of Intracellular Cytokines
Unsorted cell suspensions or B cell populations sorted by FACS
were suspended in RPMI-1640 containing 10% FBS, 100 U/ml
penicillin/ 100µg/ml streptomycin and seeded into 96 well
plates prior to stimulation with 250 ng/ml ionomycin, 50 ng/ml
PMA (both Sigma) and GolgiStop (1:1,000; BD Biosciences)
for 4 h. Cells were washed and resuspended with PBS prior to
live dead staining with Zombie Aqua. Subsequently, cells were
washed and fixed with 2% paraformaldehyde, prior to treatment
with permeabilization buffer (both eBioscience/Thermo
Fisher Scientific). Cells were stained with anti-TNFα (Mab11,
BioLegend, 1:50) and anti-IL10 (JES3-19F1, BioLegend, 1:20)
and data acquired using a FACS Canto II instrument (BD
Biosciences). See Supplemental Figure 4 for gating strategies for
analysis of cytokine production by whole CD19+ populations
from GALT and blood and Supplemental Figure 3 for sorting
CD27+IgD−, CD27−IgD−, CD27+IgD+, and CD27−IgD+
populations and for analysis of cytokine production by cultured
sorted cells.
Mass Cytometry
Cells isolated from healthy control mucosal biopsy samples (n
= 6) and IBD (UC: n = 6 and CD: n = 1) were washed and
rested in RPMI-1640 10% FBS, 100 U/ml penicillin/100µg/ml
streptomycin and DNase I (0.1 mg/ml) for 30min. Cell counts
were obtained using trypan blue (Sigma) on a Countess II FL
cell counter (Thermo Fisher Scientific). From each sample two
million live cells were stained with Cell-ID Intercalator-103
Rh (1:500; Fluidigm, San Francisco, CA, USA) for DNA for
15min. After washing cells were stained with metal-conjugated
antibodies (Supplemental Table 5) for 30min, then washed and
fixed in 2% paraformaldehyde overnight at 4◦C. Cells were
pelleted and frozen in FBS/10% DMSO at −80◦C for no longer
than 14 days. On the day of the mass cytometry run, cells were
thawed and washed prior to incubation with 0.3% saponin with
Cell-ID Intercalator-Ir for 20min to permeabilize and live/dead
stain, respectively (32). Cells were then washed with PBS followed
by twowater washes before being run into a FluidigmHeliosmass
cytometry instrument.
Data Analysis
Flow cytometry data was analyzed in FlowJo software (FlowJo
LCC, Ashland, Oregon, USA) to identify nine B cell populations,
as described in Figure 1, Supplemental Figures 1, 2, and
Supplemental Table 4. The designation of cells that do not
express IgM or IgA (or IgD for CD27− cells) as IgG+ was based
on preliminary experiments Supplemental Figure 2.
Mass cytometry data was analyzed using cloud-based
cytometry platform, Cytobank (Santa Clara, CA USA https://
mrc.cytobank.org). Bead-based normalization of the individual
mass cytometry data was performed with the Normalizer
v0.3 software from Garry P. Nolan Laboratory (downloaded
from https://github.com/nolanlab/bead-normalization/releases/
tag/v0.3). Supplemental Figure 5A shows pre and post-
normalization plots. Normalized files were gated as shown in
Supplemental Figures 5B,C after uploading onto Cytobank to
remove doublets by gating on DNA and removing cells with
implausible marker combinations. Data was generated by further
subset gating in Cytobank.
Statistical Analysis
Statistical testing was performed using GraphPad software (La
Jolla, CA, USA). Individual groups were compared using Mann-
Whitney U non-parametric test. Multiple groups were compared
using Kruskal-Wallis ANOVA. A p < 0.05 was considered
significant. Identifiers of statistical values derived from Kruskal-
Wallis ANOVA are identified with red lines and asterisks in the
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FIGURE 1 | Gating strategy for B cell subsets from blood. Gating strategy to define nine subsets of B cells using the same color code as the gating plan in
Supplemental Table 4. Further details of gating prior to the selection of CD19+ cells are in Supplemental Figure 1. Gates that define intermediate populations are
dotted. Gates that define final populations studied are solid.
figures. Identifiers of statistical values derived using the Mann-
Whitney U test are identified with black lines and asterisks in
the figures.
RESULTS
Altered B Cell Subset Frequencies in
Peripheral Blood of IBD Patients
In order to assess relative frequencies of the main B cell subsets in
peripheral blood of CD andUCpatients, we subjected the PBMCs
of patients with various disease activities and treatments (see
Supplemental Table 1) to six color flow cytometry. B cell subsets
were gated as described in Figure 1, Supplemental Figure 1 and
Supplemental Table 4. In UC blood we observed a moderate
reduction of transitional B cells (CD27−IgM+IgD+CD10+)
and an increase in marginal zone B cells (CD27+IgM+IgD+)
compared to controls (Figure 2). The frequencies of naïve,
CD27+ IgA+, and CD27+IgM+ subsets did not differ between
IBD and controls (Figure 2). In UC blood, the frequency of
CD27+IgG+ was increased compared to both HC and CD
(Figure 2). Interestingly, the most striking difference compared
to controls was the overall reduction of CD27−IgD− populations
expressing IgM, IgA or IgG in the blood of both UC and CD
patients (Figure 2).
Increased Frequencies of CD27−IgD− B
Cells in IBD GALT
Since the proportion of CD27−IgD− B cells of total CD19 B cells
was reduced in blood of patients with IBD, we asked whether
this is also a feature of B cells in GALT of patients with IBD.
To answer this specific question, we interrogated a large dataset
available in our lab that had been generated by mass cytometric
analysis of cells isolated from GALT of healthy individuals and
patients with IBD. Following initial normalization and quality
control we analyzed the data by manually gating the .fcs files in
Cytobank (Supplemental Figure 5, Supplemental Table 4 and
Figure 3). We initially gated on CD19+ cells and then excluded
CD10+ cells since these would include germinal center cells that
are not comparable with blood.We then analyzed the frequencies
of CD27+IgD−, CD27−IgD−, CD27+IgD+, and CD27−IgD+ B
cells and observed an increase in the proportion of CD27−IgD−
cells and a reduction in CD27−IgD+ cells in GALT in IBD. This
demonstrated that the CD27−IgD− B cell subset is not globally
depleted in patients with IBD.
Expression of Gut-Homing Marker Beta7
Integrin on CD27−IgD− B Cells
The enrichment of CD27−IgD− cells in GALT in IBD, and the
reduction of all subsets of this population expressing IgM, IgA,
and IgG in blood in IBD, implies that CD27−IgD− cells may be
recruited from the blood to the gut in IBD. Therefore, we went on
to investigate the gut-homing capacity of those cells in blood of
UC and CD patients by analyzing the expression of α4β7 integrin
(by staining the β7 sub-unit). In addition, we were interested
in determining whether this might differ in active disease
compared to remission state. For the analysis samples were
retrospectively stratified into raised C-reactive peptide (CRP >5
mg/l, indicating active inflammation) and normal CRP (CRP <5
mg/l). Samples were also stratified by a global clinical assessment
of the patients being having active disease compared to being
in remission.
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FIGURE 2 | Analysis of B cell subsets in healthy controls and IBD patients. Peripheral blood mononuclear cells from IBD and HC patients were stained using
fluorescent antibodies and gated according to the strategy in Figure 1 and Supplemental Table 4. Data is presented as percentage of total CD19 positive cells from
each individual HC (n = 22), UC patient (n = 17), and CD patient (n = 35). Patients with UC in are represented with blue symbols. Symbols that are lighter blue with
black borders are patients in remission. Patients with CD in are represented with green symbols. Symbols that are lighter green with black borders are patients in
remission. Differences between groups were analyzed by Mann-Whitney U test where p < 0.05 = *, p < 0.01 = **, p < 0.001 = ***, and p < 0.0001 = ****.
The frequency of CD27−IgA+ cells was slightly raised in
UC patients with CRP >5 compared to CRP<5 and the
expression of β7 integrin increased when CRP was elevated.
A similar trend was observed for the CD samples but did
not reach significance (Figures 4A,B). In UC with CRP>5,
the frequencies of CD27−IgG+ cells and CD27−IgM+IgD−
cells showed a non-significant trend toward being raised with
increased β7 expression. No differences were seen for those
two subsets and β7 in CD with a CRP>5 in terms of %
positive cells (Figure 4B), however MFI of β7 integrin expression
was lower in CD27−IgM+IgD− cells in patients with CD
when CRP was >5 compared to <5 (Supplemental Figure 6).
When patients were stratified clinically into either active disease
or in remission, we still observed a bias toward reduced
proportion of CD27−IgD− cells. The reduction of CD27−
IgD− was significantly reduced in blood from CD patients
compared to HC independently of disease activity (Figure 4C).
For the UC samples we observed a non-significant trend of
such a reduction. The expression of β7 integrin on CD27-
cells in CD blood as either % positive cells or MFI tended
to be raised but values did not reach statistical significance
(Figure 4D and Supplemental Figure 6).
Treatment With Biologics has Little Impact
on Blood CD27−IgD− Cells in IBD
Treatment escalation in advanced CD and UC cases involves
the use of biologic treatments. The most frequently used are
the anti-TNF antibody infliximab and the anti-α4β7 antibody
vedolizumab for UC and CD. The latter disease can also
be treated with the anti-p40 antibody ustekinumab. Little is
known how those antibodies affect blood B cells populations.
While we did not anticipate a direct effect of these drugs
on B cells, we wondered whether the induction of remission
and hence improved gut barrier function could have an
impact. CD27−IgD− cells have been shown to be responsive
to bacterial antigens (33). Therefore, we hypothesized that
mucosal healing during the course of treatment might affect
the proportion of CD27−IgD− B cells in the blood stream of
IBD patients. Infliximab treatment (sample obtained at week
6; “post”) did not change the frequencies of CD27−IgA+,
CD27−IgG+, or CD27− IgM+ IgD− populations compared to
the corresponding sample taken before treatment commenced
(Figure 5A). The effect of vedolizumab was also assessed at week
6 (“post”) and, interestingly, only the CD27−IgA+ population
was increased compared to the sample taken before treatment
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FIGURE 3 | B cell subsets in GALT of healthy control and IBD patients. Data was gated on the Cytobank platform. Following selection of CD19+ cells and elimination
of CD10+ cells (since these would include germinal center cells in tissues and therefore not be equivalent to CD10+ subsets in blood), cells were gated according to
their expression of CD27 and IgD. Examples of a HC and an IBD sample are illustrated in (A). In (B) dotplots represent individually gated data points for HC (n = 6),
patients with UC (n = 6 in blue) and a patient with CD in green, groups together as IBD. Groups were compared by Mann-Whitney U test where p < 0.05 = *.
(“pre”; Figure 5B), suggesting that vedolizumab retains this
population in the blood by blocking gut homing via α4β7. The
CD27−IgG−, and CD27−IgM+IgD− populations were lower in
IBD blood compared to controls but did not change during
treatment (Figure 5B). Ustekinumab treatment mildly lowered
the frequency of CD27−IgA+ cells (week 16; post, compared to
treatment start; pre. Figure 5C) but did not affect the frequencies
of CD27−IgG+, or CD27−IgM+IgD− cells (Figure 5C).
B Cells in GALT Produce TNFα and IL-10
Since our data show that B cell subsets are represented differently
in blood and GALT, we wondered whether those B cells might
be capable of producing cytokines such as TNFα and IL-10 (34).
We analyzed B cells isolated from blood and two GALT sites: the
Peyer’s patches in the terminal ileum and colonic follicles in the
rectum from the same donors for their production of intracellular
TNFα and IL10 (Supplemental Figure 4). Compared to the
donor-matched PBMCs, the B cells in healthy GALT showed
greater tendency to produce TNFα (∼25% compared to 10%).
Interestingly, slightly more B cells isolated from colonic follicles
produced TNFα than their counterparts isolated from Peyer’s
patches. B cells in GALT fromCD patients also tended to produce
more TNFα than the corresponding PBMCs (Figure 6A). In
both health and CD, PBMCs and matching GALT B cells were
able to produce IL-10 (around 20% of all B cells). There was a
non-significant trend for more B cells producing IL-10 in blood
compared to GALT (Figure 6B).
To determine if CD27−IgD− B cells might differ in cytokine
production and therefore might differ in their potential to
drive inflammation compared to other subsets, FACS sorted
CD27+IgD−, CD27−IgD−, CD27+IgD+, and CD27−IgD+ B
cells underwent intracellular staining and flow cytometry for
intracytoplasmic TNFα and IL-10 (Supplemental Figure 3).
CD27+IgD−, CD27−IgD−, CD27+IgD+ populations but fewer
CD27−IgD+ B cells had intracytoplasmic TNFα (Figure 6C).
In contrast, neither CD27+IgD−, CD27−IgD− nor CD27+IgD+
cells produced IL10 following stimulation, while between 5 and
20% CD27−IgD+ cells produced IL-10 (Figure 6D).
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FIGURE 4 | Frequency of blood CD27− IgD− subsets and β7 integrin expression in CD and UC patients stratified according to CRP levels and remission status. Three
subsets of CD27− IgD− B cells (CD27− IgA+, CD27− IgG+, and CD27− IgM+) are presented as percentage of CD19 positive cells in (A) and in (B) the percentage of
individual populations expressing of β7 integrin. For (A,B), UC < 5 n = 13, UC > 5 n = 4, CD < 5 n = 19, CD > 5 n = 16; for (C,D) HC n = 22, UC active n = 6, UC
remission n = 11, CD active n = 9 and CD remission n = 22. Data is analyzed by Mann-Whitney U test (black bars and asterisks) or Kruskal-Wallis ANOVA test (red
bars and asterisks) where p < 0.05 = *, p < 0.01 = **, p < 0.001 = *** and p < 0.0001 = ****.
DISCUSSION
In this study we aimed to gain insights into the peripheral B cell
subsets in IBD and how those subsets might differ between active
disease and the state of remission. We observed a consistent
proportionate reduction of CD27−IgD− B cells expressing IgM,
IgA, and IgG in the blood in IBD and an enrichment of the
CD27−IgD−-subset in GALT in IBD, consistent with recruitment
of CD27−IgD− B cells from the blood to the gut in IBD.
Depletion of CD27−IgD− B cells from the blood is seen in
patients with both CD and UC even when patients are in
remission and when disease activity is low. Although, differences
in transitional B cells, marginal zone B cells and CD27+IgG+ B
cells were observed, mainly between UC and controls, this could
be in compensation for the relative fall in the CD27−IgD− subset,
as populations were quantified with CD19+ cells remaining at
100% and total B cell counts were not determined. We propose
that the major feature of the data is the depletion of CD27−IgD−
subsets of B cells because this was observed consistently across
all isotypes and despite the different gating strategies required for
their identification from the blood of patients with UC and CD.
The white blood count in IBD can be altered during a
disease flare or lowered by treatments like azathioprine and
methotrexate (35). However, we also observed our findings in
Frontiers in Immunology | www.frontiersin.org 7 March 2019 | Volume 10 | Article 361
Pararasa et al. CD27- Memory B Cells in IBD
FIGURE 5 | CD27− IgD− B cells subsets in blood of CD and UC patients treated with biologics. Patients were treated with either (A) infliximab (n = 10, HC n = 9), (B)
vedolizumab (n = 6, HC n = 5), or (C) ustekinumab (n = 14, HC n = 12) with a baseline (pre) and a post-treatment (6 weeks for infliximab and vedolizumab, and 8
weeks for ustekinumab) sample obtained. Subsets of CD27− IgD− cells were compared to age and gender matched healthy controls (Dark blue squares: UC patients
responsive to treatment; Dark blue asterisks: UC patients non-responsive to treatment; Green triangles: CD patients responsive to treatment; Green asterisks: CD
patients non-responsive to treatment). Data was analyzed by Mann-Whitney U tests where p < 0.05 = *, p < 0.01 = **, p < 0.001 = *** and p < 0.0001 = ****.
patients with only mild disease or remission, and most patients
were not on treatments that cause lymphopenia, suggesting the
observed reduction of CD27−IgD− subsets is not directly linked
to treatment or a flare.
As we were interested in whether peripheral B cell subsets
are affected by disease activity in CD and UC, we stratified
patients based on their CRP values (CRP >5 mg/l as a marker of
ongoing inflammation) and based on clinical scoring by a clinical
gastroenterologist. Interestingly, we observed higher frequencies
of CD27−IgA+ cells and an increase in β7 integrin on those
cells in blood of UC patients with raised CRP levels. This was
not significant for UC patients stratified clinically (Figure 4).
Treatment with the antibody vedolizumab significantly raised
the frequency of this subset during treatment (measured at 6
weeks; Figure 5B), suggesting that blood CD27−IgA+ B cells are
retained in blood by vedolizumab which hinders gut homing
by blocking α4β7. Interestingly, treatment with infliximab and
ustekinumab did not have much effect on blood frequencies of
CD27−IgD− B cells. We only noticed a mild reduction in CD27−
IgA+ cells at 8 weeks of ustekinumab treatment (Figure 5C).
Whether this finding is of therapeutic relevance remains to
be determined.
CD27−IgD− B cells comprise∼5% of blood B cells in healthy
individuals and are considered to be part of the memory B cell
pool because they have mutations in their Ig heavy chain genes
consistent with having transited though a germinal center (23–
27). However, the role of these cells is not understood. They have
been associated with aging and inflammatory diseases including
rheumatoid arthritis (RA), systemic lupus erythematosus (SLE)
and Alzheimer’s disease, in which increased frequencies are
present in the blood (36–39). Whilst the cause of the increase
is not known, this double negative subset has been described as
responsive to anti-inflammatory treatments; anti-TNF therapy in
RA reduced the cell frequency (40), and conventional treatment
in SLE increased it (36). It is therefore very interesting that
the change in frequency of CD27−IgD− B cells in IBD is in
the opposite direction to that observed in aging and other
disease settings, and that we do not observe changes in response
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FIGURE 6 | TNFα and IL-10 expression by blood and tissue B cells. Blood (PBMC) and GALT (CF, colonic follicles; PP, Peyer’s patches) samples were obtained from
HC (n = 7) and CD patients (n = 3) and isolated CD19+ cells were analyzed for (A) TNFα and (B) IL-10 expression according to the strategy in
Supplemental Figure 4. Subsets of B cells were sorted from blood as in Supplemental Figure 3, and expression of (C) TNFα and (D) IL-10 measured. Data was
analyzed by Kruskal Wallis ANOVA test, where p < 0.05 = * and p < 0.01 = **.
to biologic therapies. As is often the case with studies of
inflammatory diseases, we cannot rule out the possibility that
medication given at some time may have induced the changes we
see. However, other inflammatory diseases may share the same
therapeutic strategies, suggesting that the reduced frequency of
CD27−IgD− B cells in IBD is a feature of the condition rather
than its treatment.
It has been suggested previously that CD27− memory B cells
are associated with intestinal B cell responses (25, 33). They
are increased in frequency in healthy GALT compared to other
lymphoid tissues (41), CD27−IgA+ memory cells have been
shown to have a distinctive repertoire and a bias toward lambda
light chain usage. They are polyspecific and able to bind multiple
bacterial species in health (33). CD27−IgA+ memory B cells
have also been reported to be generated by T cell independent
immune responses since they are present in the blood of patients
with deficient CD40/CD40L interactions (25). The increased
frequency of CD27-IgD- B cells we observe in GALT in IBD
in our study may be due to local proliferation of this subset
in response to local challenge rather than selective recruitment
from the blood. On the other hand, and in contrast, it has
also been suggested that CD27− memory B cells are part of
the normal spectrum of conventional memory B cells since
clones of B cells can span the CD27+ and CD27− subsets
(26). In this case, loss or gain of CD27 from members of a
clone may reflect time or tissue context rather than lineage or
clone specificity.
Our data linking CD27−IgD− B cells with intestinal
inflammation and their relative depletion from the blood
and enhanced frequencies in gut would be consistent with
the concept that they are a distinct population with a role
in antibacterial immunity. The mucosal barrier is known to
be disrupted to varying degrees in IBD so that the local
bacterial challenge is likely to be higher (42). UC and CD
have markedly different pathogeneses and are impacted by
different genetic predispositions and environmental drivers.
It is interesting therefore that they share the feature of
depletion of CD27− B cells from the blood. This suggests
that recruitment of CD27− B cells to the gut is more likely
a response to an intestinal challenge rather than a feature of
the disease process per se. This is potentially also the case in
quiescent IBD as persistent changes to epithelial barrier function
have been described in UC patients who had no mucosal
defects (43, 44).
Since our data shows that GALT B cells and blood B cells,
including CD27−IgD− memory cells, are able to produce TNFα,
we suggest that increased recruitment of these cells to the gut
might contribute to the inflammatory milieu in IBD.
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